Nxera and Shionogi launch Quviviq in Japan
Japanese firms Nxera Pharma - formerly known as Sosei Group or Sosei Heptares - and Shionogi (TYO: 4507) have announced that Quviviq (daridorexant) 25mg and 50 mg has been launched and is now available in the Asian country as a new treatment for adults with insomnia.
Quviviq is an oral dual orexin receptor antagonist for the treatment of insomnia that selectively binds to receptors of the wake-promoting neuropeptide orexin, OX1R and OX2R, inhibiting excessive wakefulness and facilitating the transition to sleep.
The drug was discovered by Idorsia Pharmaceuticals (SWX: IDIA) and the Swiss pharma company markets it under the same brand name in the USA, Europe and Canada.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze